364635-60-9

Usage

Chemical Properties

Off-White Solid

Upstream product

• 93-55-0 1-phenyl-propan-1-one 
• 114031-67-3 [4-(4-hydroxybenzoyl)phenyl]-2,2-dimethyl propanoate 
• 611-99-4 4,4'-Dihydroxybenzophenone 
• 111983-36-9 [4-(tert-Butyldimethylsilanyloxy)phenyl]-(4-hydroxyphenyl)methanone 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 177748-17-3 (E)-1-(4-hydroxyphenyl)-1-[4-(trimethylacetoxy)phenyl]-2-phenylbut-1-ene 
• 1308808-22-1 (Z)-4-(1-(4-(2-aminoethoxy)phenyl)-2-phenylbut-1-enyl)phenol 
• 1440533-08-3 (Z)-4-(1-(4-(2-amino-2-oxoethoxy)phenyl)-2-phenylbut-1-enyl)phenyl Pivalate 

Relevant academic research and scientific papers

NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF

The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.

ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modifed side chains

We report here the synthesis and cell-proliferation properties of derivatives of the breast cancer drug tamoxifen, in which the -O(CH 2)2N-(CH3)2 side chain, responsible for the drug's antiestrogenic properties,

Identification of new triarylethylene oxyalkanoic acid analogues as bone selective estrogen mimetics

Previously, the estrogen receptor (ER) ligand 4-[1-(p-hydroxyphenyl)-2-phenylethyl]phenoxyacetic acid (5) was found to have differential bone loss suppressive effects in the ovariectomized (OVX) rat approaching those of selective ER modulators (SERMs) suc

Synthesis and Sulfatase Inhibitory Activities of (E)- and (Z)-4-Hydroxytamoxifen Sulfamates

We report the development of (E)- and (Z)-4-hydroxytamoxifen sulfamates as estrone sulfatase inhibitors, potential therapeutic agents for the treatment of breast cancer. Both compounds competitively inhibit estrone sulfatase isolated from rat liver with apparent Ki of 35.9 μM for (E)-4-hydroxytamoxifen sulfamate and an apparent Ki of >500 μM for the (Z) isomer.